<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114414">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02041767</url>
  </required_header>
  <id_info>
    <org_study_id>P090205</org_study_id>
    <nct_id>NCT02041767</nct_id>
  </id_info>
  <brief_title>Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration</brief_title>
  <acronym>ERTAPRO</acronym>
  <official_title>Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the prostatic diffusion in significant
      concentration of ertapenem achieved after a pre-operative single administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ertapenem  is an antibiotic belonging to carbapenems family and  used in infections with
      Gram-negative bacilli with extended  spectrum beta lactamase (ESBL). Its efficacy has been
      demonstrated in abdominal, soft tissue, pulmonary, skin and gynaecological infections.
      Recently it has been compared to ceftriaxone in urinary infections demonstrating his
      efficacy and tolerance.

      The purpose of this study is to assess its benefit in probabilistic strategy by
      demonstrating its prostatic diffusion in significant concentration when administrated in a
      pre-operative single injection.

      Patients were divided in two groups receiving a single injection of 1g of ertapenem 1h or
      12h before endoscopic surgery of prostate hyperplasia.

      Concentration of ertapenem was measuring on blood sample and on chips resection of prostate
      during endoscopic surgery.

      To demonstrate the prostatic diffusion in significant amount of ertapenem, the prostatic
      concentration of ertapenem had to be higher than the minimal inhibitory concentration (MIC)
      for 40% of the time of injection interval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Prostatic concentration of ertapenem</measure>
    <time_frame>at the time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>To observe whether a significant intra-prostatic concentration of ertapenem can be obtained after a pre-operative single administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostatic concentration of ertapenem</measure>
    <time_frame>at the time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>To observe the difusion of ertapenem by comparing 1h versus12h injection prior to surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>One single injection of 1g of ertapenem before surgery</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acceptance and understanding of the consent form (signed)

          -  18-80 years old patients

          -  BPH needing endoscopic resection according to French Urology Association
             recommendations

          -  Procedure and follow up made in investigator center

          -  normal digital rectal examination

          -  PSA &lt; 10 ng/mL

          -  if 4&lt;PSA&lt;10, the ratio free PSA/total PSA must be &lt; 20%

          -  patient affiliated to the social security

        Exclusion Criteria:

          -  personal or familial history of prostatic or genito-urinary cancer

          -  personal history of pelvic irradiation

          -  personal history of hormone-therapy

          -  personal history of prostatic adenomectomy by abdominal approach

          -  personal history of allergy to beta-lactamines

          -  urinary tract infection or bacterial colonisation at the time of procedure

          -  carbapenems treatment in the two weeks before surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lortholary, Md, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Service de Maladies Infectieuses et Tropicales, Hôpital Necker, 149 rue de Sèvres</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc-Olivier Timsit, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Urologie, HEGP, 20 rue Leblanc, 75015 Paris, France.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc-Olivier Timsit, MD, PhD</last_name>
    <phone>+33 1 56 09 56 45</phone>
    <email>marc-olivier.timsit@egp.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>+33 1 58 41 35 45</phone>
    <email>laurence.lecomte@cch.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HEGP Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75908 Cedex 15</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Olivier Timsit, MD, PhD</last_name>
      <phone>+33 1 56 09 56 45</phone>
      <email>marc-olivier.timsit@egp.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Lecomte, PhD</last_name>
      <phone>+ 33 1 58 41 35 45</phone>
      <email>laurence.lecomte@cch.aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Alhambra A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alós JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004 Jun;53(6):1090-4. Epub 2004 Apr 29.</citation>
    <PMID>15117925</PMID>
  </reference>
  <reference>
    <citation>Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900.</citation>
    <PMID>12183244</PMID>
  </reference>
  <reference>
    <citation>Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002 Jul;60(1):16-22.</citation>
    <PMID>12100914</PMID>
  </reference>
  <reference>
    <citation>Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii67-74.</citation>
    <PMID>15150185</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ertapenem; prostatic diffusion; antibioprophylaxy; pharmacokinetics; benign prostatic hyperplasia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
